Palbociclib Combo Tops Chemo in High-Risk Breast Cancer

The Phase 3 PADMA trial showed that palbociclib plus endocrine therapy doubled progression-free survival compared with chemotherapy in high-risk HR+/HER2− metastatic breast cancer.
Medscape Medical News